Pharma and Biotech


FTSE 100

  • Change Today:
  • 52 Week High: 2,263.00
  • 52 Week Low: 1,641.00
  • Currency: UK Pounds
  • Shares Issued: 4,067.35m
  • Volume: 673,891
  • Market Cap: £66,900m
  • RiskGrade: 129

GlaxoSmithKline to invest £1bn in infectious disease R&D

By Michele Maatouk

Date: Thursday 23 Jun 2022

LONDON (ShareCast) - (Sharecast News) - GlaxoSmithKline said on Thursday it will invest £1bn over ten years to accelerate research and development (R&D) into infectious diseases that disproportionately impact lower-income countries.
The research will focus on new and disruptive vaccines and medicines to prevent and treat malaria, tuberculosis, HIV (through ViiV Healthcare), neglected tropical diseases and anti-microbial resistance, which Glaxo said "continue to have a devastating toll on the most vulnerable, accounting for more than 60% of the disease burden in many lower-income countries".

Thomas Breuer, GSK's chief global health officer, said: "I am delighted to renew our commitment to global health research for the coming decade, consistent with our purpose to unite our science, technology, and talent to get ahead of disease together and our ambition to deliver health impact at scale.

"Through our focus on scientific innovation in Global Health, we have delivered the first malaria vaccine, RTS,S, the first radical cure of vivax malaria, tafenoquine, and a new tuberculosis vaccine candidate."

He noted that the company now has more than 30 potential new vaccines and medicines - including pre-clinical assets - in 13 high-burden infectious diseases to accelerate.

Email this article to a friend

or share it with one of these popular networks:

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.


GSK Market Data

Currency UK Pounds
Share Price 1,644.80p
Change Today -14.60p
% Change -0.88 %
52 Week High 2,263.00
52 Week Low 1,641.00
Volume 673,891
Shares Issued 4,067.35m
Market Cap £66,900m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend
35.55% below the market average35.55% below the market average35.55% below the market average35.55% below the market average35.55% below the market average
37.50% above the sector average37.50% above the sector average37.50% above the sector average37.50% above the sector average37.50% above the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 7
Buy 1
Neutral 13
Sell 0
Strong Sell 1
Total 22
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q2 Q1
Ex-Div 18-Aug-22 19-May-22
Paid 06-Oct-22 01-Jul-22
Amount 16.25p 14.00p

Trades for 09-Aug-2022

Time Volume / Share Price
11:21 102 @ 1,644.80p
11:21 301 @ 1,644.70p
11:21 525 @ 1,644.70p
11:21 102 @ 1,644.50p
11:21 118 @ 1,644.60p

GSK Key Personnel

CEO Emma Walmsley
CFO Iain Mackay

Top of Page